Daclizumab for Treatment of Birdshot Chorioretinopathy

Anti-inflammatory treatment of uveitis with biologicals: new treatment options that reflect pathogenetic knowledge of the disease

“…Within the first year patients did not need any other immunosuppressive or anti-inflammatory therapy other than daclizumab. Meanwhile, seven additional studies have reported clinical improvement in 42 of 64 uveitis patients treated with daclizumab with a followup of 1 to 2 years [51,[124][125][126][127][128][129]. Two of these studies reported an increase in average visual acuity from 68 to 79.6 and 69.2 to 78.2 letters [124,126].…”

Treatment of Cystoid Macular Edema in a Patient With Birdshot Chorioretinopathy With Bevacizumab

“…4 Most treatment regimens include some combination of systemic or periocular corticosteroids, methotrexate, mycophenolate mofetil, daclizumab, and other systemic immunosuppressants. 5, 6 Coma et al 7 showed that intravitreal bevacizumab markedly decreases CME that is secondary to uveitis. Brue et al 8 described treating a patient with birdshot chorioretinopathy with simultaneous intravitreous injection of triamcinolone, photodynamic therapy, and bevacizumab.…”

New Biologic Drugs: Anti-Interleukin Therapy

“…In this prospective, multicenter, nonrandomized, noncomparative interventional trial, 10 of 15 patients achieved the primary end point of a ≥50% reduction of systemic corticosteroids and/or immunosuppressive regimens, and had maintained baseline visual acuity 12 and 26 weeks later. Furthermore, in other case series employing daclizumab for the treatment of birdshot chorioretinitis [58] or uveitis associated with JIA [59], inflammatory control was adequate in some patients refractory to other immunosuppressives.…”